Episodic Ataxia Type 2

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Episodic Ataxia Type 2 trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingNot Applicable

NCT01793168

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, i…

United States, Australia20,000 participantsStarted 2010-07

All recent trials (6 shown)

Not Yet RecruitingPhase 3

NCT07221292

Pivotal Study of N-acetyl-L-leucine for CACNA1A

A pivotal, randomized, double-blind, placebo-controlled, multi-center therapeutic study for patients age 4 and older with a confirmed diagnosis of CACNA1A. The…

United States, Germany, Switzerland60 participantsStarted 2026-09-01

Treatment: N-Acetyl-L-Leucine, Placebo

CompletedNot Applicable

NCT05687474

Baby Detect : Genomic Newborn Screening

Newborn screening (NBS) is a global initiative of systematic testing at birth to identify babies with pre-defined severe but treatable conditions. With a simple…

Belgium6,824 participantsStarted 2022-09-01

Episodic Ataxia Type 2

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

All recent trials (6 shown)

Pivotal Study of N-acetyl-L-leucine for CACNA1A

Baby Detect : Genomic Newborn Screening

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

All recent trials (6 shown)

Pivotal Study of N-acetyl-L-leucine for CACNA1A

Baby Detect : Genomic Newborn Screening

4-Aminopyridine in Episodic Ataxia Type 2

Biomarkers in Autosomal Dominant Cerebellar Ataxia

Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a St…